| 49058 |
Although risk of transfusion transmission is theoretical, notification of the clinician of confirmed infection in the donor may also be considered if the blood or components have been transfused.
|
尽管输血传播的风险是理论上的，但如果血液或血液成分已经输入他人体内， 也可以考虑通知临床医生献血者确诊感染的情况。
|
| 49059 |
Testing of the blood supply is premature in the absence of cases of transfusion transmission or demonstrated infectivity of the COVID-19 virus in blood collected from asymptomatic persons.
|
在没有输血传播病例或没有证据表明 COVID-19病毒在采自无症状者身上的血液中具有传染性的情况下，血液供应检测为时过早。
|
| 49060 |
Pathogen reduction technologies (PRTs) have been demonstrated to be effective against SARS-CoV and MERS-CoV in plasma and platelets. |
病原体减少技术已被证明能有效对抗血浆和血小板中的SARS-CoV和MERS-CoV。 |
| 49061 |
However, PRT requires significant logistical and financial investment. |
然而，病原体减少技术需要大量的物流和财政方面的投资。 |
| 49062 |
PRT for whole blood is less widely available and studies of inactivation of coronaviruses in whole blood are lacking. |
对全血应用病原体减少技术不太普遍，缺乏全血中冠状病毒灭活的研究。 |
| 49063 |
Introduction of PRT for the COVID-19 virus would not be cost effective or proportionate and is not recommended.
|
将病原体减少技术应用于 COVID-19病毒既不划算也不适当，因此不推荐。
|
| 49064 |
Current manufacturing processes for plasma derivatives can inactivate and remove viruses related to the COVID-19 virus. |
目前血浆衍生物的生产工艺可以灭活和去除与COVID-19病毒相关的病毒。 |
| 49065 |
As an enveloped virus, the COVID-19 virus is susceptible to many of the steps involved in preparation of therapeutic agents from fractionated plasma; thus, there is no presumed risk for transmission through these products.
|
作为一种包膜病毒，COVID-19病毒对从分级血浆中制备治疗剂的许多步骤敏感；因此， 不存在通过这些产品传播病毒的假定风险。
|
| 49066 |
A haemovigilance system should be in place to capture any possible cases of transmission through blood and components. |
应建立血液监测系统，以捕捉任何通过血液和血液成分传播病毒的可能病例。 |
| 49067 |
Haemovigilance is invaluable in helping to understand the risk from blood and components and the overall effectiveness of the measures taken by the blood service. |
血液监测在帮助了解血液和血液成分的风险以及血液中心所采取措施的总体有效性方面非常重要。
|